NCT05662020View on ClinicalTrials.gov

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

2,750

Participants

Timeline

Start Date

March 23, 2022

Primary Completion Date

November 7, 2022

Study Completion Date

March 23, 2028

Conditions
Human Papillomavirus Infection
Interventions
BIOLOGICAL

Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.

BIOLOGICAL

GARDASIL® 9

20-26 years possitive control group will be vaccinated at months 0, 2 and 6

Trial Locations (1)

650022

Yunnan Center for Disease Prevention and Control, Kunming

Sponsors
All Listed Sponsors
collaborator

Yunnan Center for Disease Control and Prevention

OTHER

collaborator

Mile City Center for Disease Control and Prevention

UNKNOWN

collaborator

Qiubei County Center for Disease Control and Prevention

UNKNOWN

collaborator

Yanshan County Center for Disease Control and Prevention

UNKNOWN

collaborator

National Institutes for Food and Drug Control, China

OTHER

collaborator

Shanghai Stem Pharmaceutical Development Co., Ltd.

UNKNOWN

lead

Beijing Health Guard Biotechnology, Inc

INDUSTRY